The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q1 2022 call → NO我们根据指令判断管理层是否传达出报告期结果不代表当前实际业务。关键点:管理层是否反复或实质性地表明报告期数字已过时,当前业务已超越报告期。 分析内容: - 管理层提到Q1业绩超预期,但强调3月创纪录的注册量可能包含积压需求,且4月表现令人鼓舞。 - 提到NGS定价更新于4月1日生效,对Q1无贡献,但将在下半年带来收益。 - 提到下一代生物传感器Zio monitor已发货首批用于首次患者使用,但全面商业化在2023年。 - 提到国际扩张计划(德国、法国等)即将启动,但尚未贡献收入。 - 提到Zio Watch仍在FDA审查中,未商业化。 - 管理层在回答问题时强调核心市场仍有大量增长空间,但未明确表示当前业务已超越报告期。 关键判断:管理层是否明确表示报告期数字已过时?他们提到Q1业绩强劲,但指出部分增长可能来自积压需求,且NGS定价和下一代产品尚未贡献。然而,这些属于常规的“未来增长动力”描述,而非强调报告期已落后于当前业务。管理层没有说“报告期不代表我们现在的水平”,而是说“我们正在为未来增长做准备”。因此,不符合“报告期已过时”的表述。 结论:NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.